Literature DB >> 7770931

Red cell alloantibody development associated with heart and lung transplantation.

D Cummins1, M Contreras, S Amin, O Halil, B Downham, M H Yacoub.   

Abstract

The development and persistence of clinically significant red cell alloantibodies were studied in 1132 patients who underwent a heart and/or lung transplant at Harefield Hospital. Clinically significant antibodies were detected in 15 patients (1.3%) preoperatively and appeared in a further 15 (2.1%) of 704 patients followed up 1-404 weeks after surgery. Anti-D developed in only 1 of 52 D-negative recipients of a D-positive donor graft and in only 2 of 6 D-negative patients who were transfused with between 6 and 32 units of D-positive red cells. Most antibodies that appeared after transplantation remained detectable for only a few weeks. Antibodies detected preoperatively that reacted only with papain-treated cells became persistently undetectable in 4 patients who were transfused with red cells expressing the corresponding antigen specificity. By contrast, antibodies detected preoperatively by indirect antiglobulin test were still detectable after periods of up to 260 weeks in 4 patients who received only antigen-negative red cells. Immunosuppressive therapy appeared to profoundly affect the natural history of red cell alloantibody production in these patients. The underlying mechanisms warrant further study.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7770931     DOI: 10.1097/00007890-199505270-00013

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

1.  Platelet transfusion - the art and science of compromise.

Authors:  Joan Cid; Sarah K Harm; Mark H Yazer
Journal:  Transfus Med Hemother       Date:  2013-04-26       Impact factor: 3.747

2.  Frequency of alloantibodies among chronic renal failure patients in red sea state.

Authors:  Hythum Abdullah M Babiker; Tagwa Yousif Elsayed
Journal:  Indian J Hematol Blood Transfus       Date:  2013-02-12       Impact factor: 0.900

Review 3.  Responder individuality in red blood cell alloimmunization.

Authors:  Günther F Körmöczi; Wolfgang R Mayr
Journal:  Transfus Med Hemother       Date:  2014-10-28       Impact factor: 3.747

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.